 |
市場調查報告書
商品編碼
1616276
阿黴素市場機會、成長動力、產業趨勢分析和 2024 年至 2032 年預測Doxorubicin Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032 |
||||||
2023 年，全球阿黴素市場價值為13 億美元，預計2024 年至2032 年複合年成長率為6.3%。於治療各種癌症。它破壞癌細胞的 DNA，阻止其生長和分裂，最終導致細胞死亡。全球癌症發病率的飆升極大地推動了市場的擴張。例如，世界衛生組織(WHO) 報告稱，2022 年預計將有2,000 萬新癌症病例和970 萬名癌症相關死亡病例。上升的癌症負擔需要晚期和癌症治療。
此外，化療的創新、對個人化醫療的重視以及政府對癌症研究投資的增加進一步促進了阿黴素市場的收入成長。整個阿黴素產業根據應用、藥物配方、配銷通路和地區進行分類。以劑型分類，阿黴素市場包括冷凍乾燥粉針劑和阿黴素注射劑。預測顯示，到 2032 年，阿黴素注射液市場將達到 13 億美元。 阿黴素可有效治療多種癌症，包括但不限於乳癌、淋巴瘤、白血病和肉瘤。
其廣譜功效使其成為關鍵的治療選擇。可注射的變體增強了這種多功能性，確保快速作用和全身治療，使藥物能夠迅速作用於全身的癌細胞。阿黴素的應用範圍涵蓋肝癌、乳癌、肺癌和腎癌等。 2023 年，光是乳癌領域就創造了 3.018 億美元的收入。
| 市場範圍 | |
|---|---|
| 開始年份 | 2023年 |
| 預測年份 | 2024-2032 |
| 起始值 | 13億美元 |
| 預測值 | 22億美元 |
| 複合年成長率 | 6.3% |
由於其廣泛的癌細胞靶向性，阿黴素的適應性使其能夠應用於從早期檢測到轉移階段的所有乳癌階段。這種靈活性不僅鞏固了其在不同臨床場景中的重要性，而且解釋了乳癌細分市場的主導市場佔有率。在美國，阿黴素市場預計到 2032 年將達到 7.717 億美元。美國疾病管制與預防中心 (CDC) 的數據顯示，2020 年，新診斷出 1,603,844 例癌症，其中 602,347 例死亡。此外，美國擁有先進的醫療保健框架，擁有先進的醫院和專門的癌症中心，確保阿黴素治療的最佳管理。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 癌症盛行率增加
- 化療治療的進展
- 日益關注個人化醫療
- 政府對癌症研究的資助增加
- 產業陷阱與挑戰
- 替代療法的可用性
- 與藥物相關的副作用
- 成長動力
- 成長潛力分析
- 技術景觀
- 監管環境
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按藥物配方，2021 - 2032 年
- 主要趨勢
- 凍乾粉
- 阿黴素注射液
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 乳癌
- 肝癌
- 腎癌
- 肉瘤
- 卵巢癌
- 肺癌
- 白血病
- 多發骨髓瘤
- 其他類型的癌症
第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥房
- 網路藥房
第 8 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- Accord Healthcare
- Baxter International Inc.
- Cipla Ltd.
- Dr. Reddy's Laboratories Limited
- Fresenius SE & Co. KGaA
- Johnson and Johnson
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Meiji Holdings Co. Ltd.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Zydus Lifesciences Limited
The Global Doxorubicin Market was valued at USD 1.3 billion in 2023 and is projected to depict a 6.3% CAGR from 2024 to 2032. Doxorubicin, derived from the bacterium Streptomyces Peucetius, is an anthracycline-based chemotherapy drug predominantly used to treat various cancers. It disrupts the DNA of cancer cells, halting their growth and division, and ultimately leading to cell death. The surging global cancer incidence significantly propels the market's expansion. For example, the World Health Organization (WHO) reported an estimated 20 million new cancer cases and 9.7 million cancer-related deaths in 2022. Such statistics highlight the escalating demand for potent chemotherapy agents like doxorubicin, as the rising cancer burden calls for advanced and widely adopted treatment modalities.
Moreover, innovations in chemotherapy, an emphasis on personalized medicine, and heightened government investments in cancer research further bolster the doxorubicin market's revenue growth. The overall doxorubicin industry is classified based on application, drug formulation, distribution channel, and region. Segmented by drug formulations, the doxorubicin market comprises lyophilized powder and doxorubicin injection. Projections suggest the doxorubicin injection segment will hit USD 1.3 billion by 2032. Doxorubicin effectively targets a myriad of cancers, including but not limited to breast cancer, lymphoma, leukemia, and sarcoma.
Its broad-spectrum efficacy positions it as a pivotal treatment choice. The injectable variant amplifies this versatility, ensuring swift action and systemic treatment, allowing the drug to promptly engage cancer cells throughout the body. Applications of doxorubicin span liver, breast, lung, and kidney cancers, among others. In 2023, the breast cancer segment alone generated USD 301.8 million.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $1.3 Billion |
| Forecast Value | $2.2 Billion |
| CAGR | 6.3% |
Doxorubicin's adaptability allows its application across all breast cancer stages, from early detection to metastatic phases, thanks to its broad cancer cell targeting. This flexibility not only solidifies its significance in varied clinical scenarios but also explains the breast cancer segment's dominant market share. In the U.S., the doxorubicin market is on track to reach USD 771.7 million by 2032. The rising cancer prevalence in the U.S. significantly fuels the doxorubicin market's growth. Data from the Centers for Disease Control and Prevention (CDC) indicates that in 2020, there were 1,603,844 new cancer diagnoses, with 602,347 resulting in fatalities.Such rising figures underscore the urgent demand for effective therapeutic solutions. Moreover, the U.S. is home to a sophisticated healthcare framework, featuring advanced hospitals and specialized cancer centers, ensuring optimal management of doxorubicin therapies.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of cancer
- 3.2.1.2 Advancements in chemotherapy treatments
- 3.2.1.3 Growing focus on personalized medicine
- 3.2.1.4 Growth in government funding for cancer research
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Availability of alternative therapies
- 3.2.2.2 Side effects associated with the medication
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Technology landscape
- 3.5 Regulatory landscape
- 3.6 Future market trends
- 3.7 Porter's analysis
- 3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Formulation, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Lyophilized powder
- 5.3 Doxorubicin injection
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Breast cancer
- 6.3 Liver cancer
- 6.4 Kidney cancer
- 6.5 Sarcoma
- 6.6 Ovarian cancer
- 6.7 Lung cancer
- 6.8 Leukemia
- 6.9 Multiple myeloma
- 6.10 Other types of cancer
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacy
- 7.3 Retail pharmacy
- 7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 Accord Healthcare
- 9.2 Baxter International Inc.
- 9.3 Cipla Ltd.
- 9.4 Dr. Reddy's Laboratories Limited
- 9.5 Fresenius SE & Co. KGaA
- 9.6 Johnson and Johnson
- 9.7 Hikma Pharmaceuticals PLC
- 9.8 Lupin Limited
- 9.9 Meiji Holdings Co. Ltd.
- 9.10 Novartis AG
- 9.11 Pfizer Inc.
- 9.12 Sun Pharmaceutical Industries Ltd.
- 9.13 Sanofi
- 9.14 Teva Pharmaceutical Industries Ltd.
- 9.15 Viatris Inc.
- 9.16 Zydus Lifesciences Limited
